Literature DB >> 15957152

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.

Jorge S Reis-Filho1, Pete T Simpson, Chris Jones, Dawn Steele, Alan Mackay, Marjan Iravani, Kerry Fenwick, Haukur Valgeirsson, Maryou Lambros, Alan Ashworth, Jose Palacios, Fernando Schmitt, Sunil R Lakhani.   

Abstract

Immunohistochemical analysis of E-cadherin has changed the way lobular neoplasia is perceived. It has helped to classify difficult cases of carcinoma in situ with indeterminate features and led to the identification of new variants of lobular carcinoma. Pleomorphic lobular carcinoma (PLC) and pleomorphic lobular carcinoma in situ (PLCIS), recently described variants of invasive and in situ classic lobular carcinoma, are reported to be associated with more aggressive clinical behaviour. Although PLC/PLCIS show morphological features of classic lobular neoplasia and lack E-cadherin expression, it is still unclear whether these lesions evolve through the same genetic pathway as lobular carcinomas or are high-grade ductal neoplasms that have lost E-cadherin. Here we have analysed a case of extensive PLCIS and invasive PLC associated with areas of E-cadherin-negative carcinoma in situ with indeterminate features, using immunohistochemistry, chromogenic in situ hybridization, high-resolution comparative genomic hybridization (CGH) and array-based CGH. We observed that all lesions lacked E-cadherin and beta-catenin and showed gain of 1q and loss of 16q, features that are typical of lobular carcinomas but are not seen in high-grade ductal lesions. In addition, amplifications of c-myc and HER2 were detected in the pleomorphic components, which may account for the high-grade features in this case and the reported aggressive clinical behaviour of these lesions. Taken together, these data suggest that at least some PLCs may evolve from the same precursor or through the same genetic pathway as classic lobular carcinomas. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957152     DOI: 10.1002/path.1806

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  35 in total

1.  Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.

Authors:  Marina De Brot; Starr Koslow Mautner; Shirin Muhsen; Victor P Andrade; Anita Mamtani; Melissa Murray; Dilip Giri; Rita A Sakr; Edi Brogi; Tari A King
Journal:  Breast Cancer Res Treat       Date:  2017-06-13       Impact factor: 4.872

2.  [The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis].

Authors:  H Bürger; C Kersting; D Hungermann; T Decker; W Böcker
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

3.  Defining ploidy-specific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines.

Authors:  Grace Ng; Jingxiang Huang; Ian Roberts; Nicholas Coleman
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma.

Authors:  Sonia Narendra; Sarah M Jenkins; Andras Khoor; Aziza Nassar
Journal:  Ann Diagn Pathol       Date:  2015-01-22       Impact factor: 2.090

5.  Molecular classification of breast carcinoma in situ.

Authors:  Usha Raju; Lu Mei; Sethi Seema; Qureshi Hina; Sandra R Wolman; Maria J Worsham
Journal:  Curr Genomics       Date:  2006       Impact factor: 2.236

Review 6.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

7.  Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.

Authors:  Rita A Mukhtar; Gregor Krings; Yunn-Yi Chen; Matina E Mamounas; Kelly Fahrner-Scott; Jasmine Wong; Michael Alvarado; Cheryl Ewing; Laura J Esserman; Hope Rugo
Journal:  Breast Cancer Res Treat       Date:  2020-04-02       Impact factor: 4.872

8.  Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17.

Authors:  Natalya Khilko; Jianmin Wang; Bing Wei; David G Hicks; Ping Tang
Journal:  Breast Cancer (Auckl)       Date:  2010-10-21

9.  Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Authors:  Yunn-Yi Chen; Eun-Sil Shelley Hwang; Ritu Roy; Sandy DeVries; Joseph Anderson; Chrystal Wa; Patrick L Fitzgibbons; Timothy W Jacobs; Gaetan MacGrogan; Hans Peterse; Anne Vincent-Salomon; Taku Tokuyasu; Stuart J Schnitt; Frederic M Waldman
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

10.  Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

Authors:  Elizabeth Iorns; Christopher J Lord; Anita Grigoriadis; Sarah McDonald; Kerry Fenwick; Alan Mackay; Charles A Mein; Rachael Natrajan; Kay Savage; Narinder Tamber; Jorge S Reis-Filho; Nicholas C Turner; Alan Ashworth
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.